

REMARKS

Favorable reconsideration of the above named patent application is respectfully requested in view of the above amendments. Following the above amendments, claims 61-69 are under consideration.

Applicants wish to thank the Examiner for the telephone conversation of June 6, 2002. As noted by the Examiner, the claims were erroneously numbered from 60-68 and claim 60 recited the nonelected sequence of SEQ ID NO:309. With the above amendments, the claims have been renumbered as 61-69 and claim 61 (formerly claim 60) now recites the elected sequence of SEQ ID NO:299. Favorable consideration of the pending claims are earnestly solicited. The Examiner is invited to contact the undersigned with any further questions, comments and/or suggestions relating to this matter.

Respectfully submitted,

SEED Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

Enclosures:

Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

C:\N:\Portbl\Manage\JULIEU\290981_1.DOC

09/534,825

210121.419C7

VERSION WITH MARKINGS TO SHOW CHANGES MADE

6160. (New) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:~~309~~299, wherein said polypeptide is expressed in breast tumor tissue.

~~61~~62. (New) An isolated polypeptide that is 90% identical to the amino acid sequence of SEQ ID NO:299, wherein said polypeptide is expressed in breast tumor tissue.

~~62~~63. (New) An isolated polypeptide according to claim 62, wherein said polypeptide is 95% identical to the amino acid sequence of SEQ ID NO:299.

~~63~~64. (New) An isolated polypeptide comprising the amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:292.

~~64~~65. (New) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:299.

~~65~~66. (New) An isolated polypeptide according to claim 61, in combination with a physiologically acceptable carrier.

~~66~~67. (New) An isolated polypeptide according to claim 61, in combination with an immunostimulant.

6768. (New) An isolated polypeptide according to claim 67, wherein
said immunostimulant is an adjuvant.

6869. (New) An isolated polypeptide according to claim 67, wherein
said immunostimulant induces a predominantly Type I response.

C:\N\Portbl\iManage\JULIEU\290981_1.DOC